Medical Doctor Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jorge Gomez Alarcon

Hospitalist Lake Forest, IL Medical Doctor

NPI 1487183604 CMS profile 3169858

1000 N Westmoreland Rd, Lake Forest, IL 60045

Open in the dashboard

General payments

$71,697

381 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jorge Gomez Alarcon of Lake Forest, IL is reported in the CMS Open Payments database as having received $71,697 across 381 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Hospitalist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,367 70
2024 General $23,616 122
2023 General $24,934 100
2022 General $7,010 43
2021 General $3,770 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jorge Gomez Alarcon
  • Hospitalist median
  • Middle half of Hospitalist
  • National median

In program year 2025, general payments to Jorge Gomez Alarcon were reported at $12,367. Among 6,882 Hospitalist profiles paid that year, the median was $86 and the middle half received between $30 and $191.

Show as a table
Year Jorge Gomez Alarcon Hospitalist median Middle half National median
2019 $0 $96 $28–$201 $163
2020 $0 $48 $19–$125 $114
2021 $3,770 $70 $23–$167 $132
2022 $7,010 $85 $27–$174 $149
2023 $24,934 $89 $30–$191 $160
2024 $23,616 $95 $29–$204 $164
2025 $12,367 $86 $30–$191 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $24,540 115 payments
  2. Boston Scientific Corporation $14,839 50 payments
  3. Medtronic, Inc. $11,224 49 payments
  4. Biotronik Inc. $9,663 47 payments
  5. Medical Device Business Services, Inc. $5,923 27 payments
  6. Biosense Webster, Inc. $2,468 38 payments
  7. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,196 19 payments
  8. Janssen Pharmaceuticals, Inc $689 10 payments
  9. Philips Electronics North America Corporation $272 3 payments
  10. Chiesi USA, Inc. $148 3 payments
  11. Other $734 20 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Travel and Lodging $29,029 86 payments
  2. Grant $25,625 9 payments
  3. Food and Beverage $15,736 279 payments
  4. Education $1,307 7 payments
Products named General payments · program years 2021–2025
  1. Carto 3 $8,308 64 payments
  2. ENSITE PRECISION $8,030 50 payments
  3. General - EP $2,167 7 payments
  4. EnSite Precision Cardiac Mapping System $1,602 17 payments
  5. EMBLEM MRI S-ICD $1,528 11 payments
  6. Micra $1,293 6 payments
  7. LifeVest $1,196 19 payments
  8. Solia $1,180 5 payments
  9. PAMIRA $1,086 5 payments
  10. VersaCross Access Solution $1,065 1 payment
  11. Other $10,534 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

158

Median for Hospitalist: 109

Drug cost

$41,680

Median for Hospitalist: $6,399

Branded share of claims

43.7%

Median for Hospitalist: 19.5%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 28 $23,835
Multaq Dronedarone Hcl Brand 11 $13,033
Jardiance Empagliflozin Brand 11 $3,517
Pantoprazole Sodium Generic 17 $474
Metoprolol Succinate Generic 22 $298
Sucralfate Generic 20 $206
Clopidogrel Clopidogrel Bisulfate Brand 19 $134
Amiodarone Hcl Generic 11 $131
Cephalexin Generic 19 $52

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,498 Part D prescribers listed as Hospitalist; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$10,098

Medicare's payments for the services billed

Medicare patients

83

Average age 77

Services billed

123

40 women, 43 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 65%
Ischemic heart disease 64%
Chronic kidney disease 57%
Heart failure 47%
Diabetes 42%
Atrial fibrillation 40%
Cancer 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

381 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hospitalist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record